Table 3 |
||||
|
Drugs with significant enrichment to diurnal signature in the Connectivity Map |
||||
|
rank |
drug |
mean |
n |
p-value |
|
|
||||
|
1 |
sirolimus |
0.68 |
10 |
0 |
|
2 |
LY-294002 |
0.54 |
17 |
0 |
|
3 |
wortmannin |
0.62 |
8 |
0.0001 |
|
4 |
trichostatin A |
0.48 |
12 |
0.0012 |
|
5 |
resveratrol |
0.61 |
5 |
0.0026 |
|
6 |
5182598 |
-0.78 |
2 |
0.0043 |
|
7 |
estradiol |
-0.39 |
10 |
0.0079 |
|
8 |
iloprost |
-0.71 |
3 |
0.0105 |
|
9 |
tacrolimus |
-0.56 |
3 |
0.0153 |
|
10 |
arachidonyltrifluoromethane |
-0.75 |
2 |
0.02 |
|
11 |
deferoxamine |
0.49 |
3 |
0.0292 |
|
12 |
fludrocortisone |
-0.60 |
2 |
0.0429 |
|
13 |
quercetin |
-0.53 |
2 |
0.0607 |
|
14 |
TTNPB |
-0.57 |
2 |
0.0645 |
|
15 |
vorinostat |
0.53 |
2 |
0.0734 |
|
16 |
fulvestrant |
0.39 |
7 |
0.0858 |
|
17 |
raloxifene |
-0.15 |
3 |
0.0876 |
|
18 |
rottlerin |
0.43 |
3 |
0.0945 |
|
|
||||
|
The drugs with significant connectivity to the diurnal signature are ranked in the order of significance of the connectivity score as judged by the permutation p-value (column labeled "p-value"). Significance cut-off was set at pvalue = 0.1. The permutation p-value estimates the likelihood that the enrichment of a given set of post-dose gene expression changes (instances) by a given drug, relative to all available post-dose changes in the CMAP database (for all drugs) would be observed by random chance. Mean: the arithmetic mean of the connectivity scores for the post-dose changes by the given drug; N: the number of instances of a given drug in CMAP database[23]. |
||||
|
Loboda et al. BMC Medical Genomics 2009 2:7 doi:10.1186/1755-8794-2-7 |
||||
